Literature DB >> 32519370

Effects of PPAR-γ agonists on oral cancer cell lines: Potential horizons for chemopreventives and adjunctive therapies.

Jeffrey A Hall1, Mark Rusten2, Raed D Abughazaleh3, Beverly Wuertz3, Vannesa Souksavong4, Paul Escher4, Frank Ondrey3.   

Abstract

BACKGROUND: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) activators have anti-cancer effects. Our objective was to determine the effect of PPAR-γ ligands 15-deoxy-D12,14 -Prostaglandin J2 (15-PGJ2 ) and ciglitazone on proliferation, apoptosis, and NF-κB in human oral squamous cell carcinoma cell lines.
METHODS: NA and CA9-22 cells were treated in vitro with 15-PGJ2 and ciglitazone. Proliferation was measured by MTT colorimetric assay and cell cycle analysis performed via flow cytometry, apoptosis by caspase-3 colorimetric assay and poly-(ADP-ribose) polymerase cleavage on Western blot, and NF-κB activation by luciferase assays.
RESULTS: MTT assays demonstrated dose-dependent decreases after 15-PGJ2 treatment in both cell lines, and S-phase cell cycle arrest was also demonstrated. NF-κB luciferase reporter gene activity decreased seven- and eightfold in NA and CA9-22 cells, respectively. Caspase-3 activity increased two- and eightfold in NA and CA9-22 cells, respectively.
CONCLUSIONS: Our results suggest these agents, in addition to activating PPAR-γ, can downregulate NF-κB and potentiate apoptosis in oral cancer cells.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  15-deoxy-D12,14-prostaglandin J2 (15-PGJ2); Ciglitazone; NF-κB; PPAR-γ; squamous cell carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32519370      PMCID: PMC7657659          DOI: 10.1002/hed.26286

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  48 in total

1.  Prostaglandin-macromolecule interactions. I. Noncovalent binding of prostaglandins A1, E1, F2alpha, and E2 by human and bovine serum albumins.

Authors:  F L Gueriguian
Journal:  J Pharmacol Exp Ther       Date:  1976-05       Impact factor: 4.030

2.  An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies.

Authors:  Rikako Suzuki; Hiroyuki Kohno; Masumi Suzui; Naoki Yoshimi; Hiroyuki Tsuda; Keiji Wakabayashi; Takuji Tanaka
Journal:  Carcinogenesis       Date:  2005-10-11       Impact factor: 4.944

3.  Cigarette smoke condensate induces nuclear factor kappa-b activity and proangiogenic growth factors in aerodigestive cells.

Authors:  Joseph Rohrer; Beverly R K Wuertz; Frank Ondrey
Journal:  Laryngoscope       Date:  2010-08       Impact factor: 3.325

4.  Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.

Authors:  Donna E Seabloom; Arthur R Galbraith; Anna M Haynes; Jennifer D Antonides; Beverly R Wuertz; Wendy A Miller; Kimberly A Miller; Vernon E Steele; Chen S Suen; M Gerard O'Sullivan; Frank G Ondrey
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-19

5.  A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.

Authors:  Robert L Keith; Patrick J Blatchford; Daniel T Merrick; Paul A Bunn; Brandi Bagwell; Lori D Dwyer-Nield; Mary K Jackson; Mark W Geraci; York E Miller
Journal:  Cancer Prev Res (Phila)       Date:  2019-07-15

6.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis.

Authors:  Y Tsubouchi; H Sano; Y Kawahito; S Mukai; R Yamada; M Kohno; K Inoue; T Hla; M Kondo
Journal:  Biochem Biophys Res Commun       Date:  2000-04-13       Impact factor: 3.575

Review 7.  Evidence for an S-phase checkpoint regulating DNA replication after heat shock: a review.

Authors:  G Iliakis; T Krieg; J Guan; Y Wang; D Leeper
Journal:  Int J Hyperthermia       Date:  2004-03       Impact factor: 3.914

8.  Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model.

Authors:  Christopher M Lyon; Donna M Klinge; Kieu C Do; Marcie J Grimes; Cindy L Thomas; Leah A Damiani; Thomas H March; Christine A Stidley; Steven A Belinsky
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

9.  Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor.

Authors:  K L Gearing; M Göttlicher; M Teboul; E Widmark; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

10.  15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells.

Authors:  N G Nikitakis; H Siavash; C Hebert; M A Reynolds; A W Hamburger; J J Sauk
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

View more
  1 in total

Review 1.  Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.

Authors:  Ana Lago-Fernandez; Sara Zarzo-Arias; Nadine Jagerovic; Paula Morales
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.